Literature DB >> 12477875

CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5.

Aarti Raja1, Miro Venturi, Peter Kwong, Joseph Sodroski.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) gp120 exterior glycoprotein is conformationally flexible. Upon binding the host cell receptor, CD4, gp120 assumes a conformation that is able to bind the chemokine receptors CCR5 or CXCR4, which act as coreceptors for the virus. CD4-binding-site (CD4BS) antibodies are neutralizing antibodies elicited during natural infection that are directed against gp120 epitopes that overlap the binding site for CD4. Recent studies (S. H. Xiang et al., J. Virol. 76:9888-9899, 2002) suggest that CD4BS antibodies recognize conformations of gp120 distinct from the CD4-bound conformation. This predicts that the binding of CD4BS antibodies will inhibit chemokine receptor binding. Here, we show that Fab fragments and complete immunoglobulin molecules of CD4BS antibodies inhibit CD4-independent gp120 binding to CCR5 and cell-cell fusion mediated by CD4-independent HIV-1 envelope glycoproteins. These results are consistent with a model in which the binding of CD4BS antibodies limits the ability of gp120 to assume a conformation required for coreceptor binding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12477875      PMCID: PMC140634          DOI: 10.1128/jvi.77.1.713-718.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Proteinminus signProtein Interactions: Interface Structure, Binding Thermodynamics, and Mutational Analysis.

Authors:  Wesley E. Stites
Journal:  Chem Rev       Date:  1997-08-05       Impact factor: 60.622

2.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

Authors:  L Wu; N P Gerard; R Wyatt; H Choe; C Parolin; N Ruffing; A Borsetti; A A Cardoso; E Desjardin; W Newman; C Gerard; J Sodroski
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

3.  Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization.

Authors:  E A Emini; P Ostapchuk; E Wimmer
Journal:  J Virol       Date:  1983-11       Impact factor: 5.103

4.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication.

Authors:  P Kolchinsky; T Mirzabekov; M Farzan; E Kiprilov; M Cayabyab; L J Mooney; H Choe; J Sodroski
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

6.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

7.  Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms.

Authors:  C Wohlfart
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

8.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization.

Authors:  S Ugolini; I Mondor; P W Parren; D R Burton; S A Tilley; P J Klasse; Q J Sattentau
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

View more
  14 in total

1.  In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

Authors:  Maria Luisa Visciano; Michael Tuen; Miroslaw K Gorny; Catarina E Hioe
Journal:  Virology       Date:  2007-12-04       Impact factor: 3.616

Review 2.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

3.  Human immunodeficiency virus-associated dementia: a link between accumulation of viral proteins and neuronal degeneration.

Authors:  Italo Mocchetti; Alessia Bachis; Giuseppe Esposito; Scott R Turner; Francesca Taraballi; Ennio Tasciotti; Mikell Paige; Valeriya Avdoshina
Journal:  Curr Trends Neurol       Date:  2014

4.  Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.

Authors:  Royce A Wilkinson; Chayne Piscitelli; Martin Teintze; Lisa A Cavacini; Marshall R Posner; C Martin Lawrence
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.

Authors:  Emily J Platt; Danielle M Shea; Patrick P Rose; David Kabat
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.

Authors:  B K Chakrabarti; L M Walker; J F Guenaga; A Ghobbeh; P Poignard; D R Burton; R T Wyatt
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

7.  Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.

Authors:  Syna Kuriakose Gift; Isaac J Zentner; Arne Schön; Karyn McFadden; M Umashankara; Srivats Rajagopal; Mark Contarino; Caitlin Duffy; Joel R Courter; Mei-Yun Zhang; Jonathan M Gershoni; Simon Cocklin; Dimiter S Dimitrov; Amos B Smith; Ernesto Freire; Irwin M Chaiken
Journal:  Biochemistry       Date:  2011-03-18       Impact factor: 3.162

8.  Highly conserved beta16/beta17 beta-hairpin structure in human immunodeficiency virus type 1 YU2 gp120 is critical for CCR5 binding.

Authors:  Alain Mechulam; Martine Cerutti; Martine Pugnière; Dorothée Missé; Johanna Gajardo; Françoise Roquet; James Robinson; Francisco Veas
Journal:  J Mol Med (Berl)       Date:  2005-05-19       Impact factor: 4.599

9.  The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120.

Authors:  Catarina E Hioe; Maria Luisa Visciano; Rajnish Kumar; Jianping Liu; Ethan A Mack; Rachel E Simon; David N Levy; Michael Tuen
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

Review 10.  "Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches.

Authors:  Tanushree Malik; Gaurav Chauhan; Goutam Rath; R S R Murthy; Amit K Goyal
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.